Biopharmaceuticals expressing

Chebolu, S. and Daniell, H. (2009). Chloroplast-derived vaccine antigens and biopharmaceuticals expression, folding, assembly, and functionality. Curr. 

Knablein, )., Biopharmaceuticals expressed in plants a new era in the new Millennium, in Applications in Pharmaceutical Biotechnology. R. Muller O. Kayser (Eds.). Wiley-VCH. 

Rader R (2008). Biopharmaceutical Expression Systems and Genetic Engineering Technologies. BioPlan Associates, Inc. http //www.bioplanassociates.com/es/index.htm... 

In this review, we focus on the use of plant tissue culture to produce foreign proteins that have direct commercial or medical applications. The development of large-scale plant tissue culture systems for the production of biopharmaceutical proteins requires efficient, high-level expression of stable, biologically active products. To minimize the cost of protein recovery and purification, it is preferable that the expression system releases the product in a form that can be harvested from the culture medium. In addition, the relevant bioprocessing issues associated with bioreactor culture of plant cells and tissues must be addressed. 

As indicated in Table 2.1, most of the promoters used in plant tissue culture have been based on the constitutive cauliflower mosaic virus (CaMV) 35S promoter. In contrast, inducible promoters have the advantage of allowing foreign proteins to be expressed at a time that is most conducive to protein accumulation and stability. Although a considerable number of inducible promoters has been developed and used in plant culture applications, e.g. [32-37], the only one to be applied thus far for the production of biopharmaceutical proteins is the rice a-amylase promoter. This promoter controls the production of an a-amylase isozyme that is one of the most abundant proteins secreted from cultured rice cells after sucrose starvation. The rice a-amylase promoter has been used for expression of hGM-CSF [10], aranti-trypsin [12, 29, 38, 39] and human lysozyme [30]. 

Biopharmaceutical proteins/Vaccines Gene Site erf Integration Promoter S /3 regulatory %tsp elements expression Laboratory... 

Several key issues have to be addressed in the downstream processing of biopharmaceuticals regardless of the expression system. The removal of host cell proteins and nucleic acids, as well as other product- or process-related or adventitious contaminants, is laid down in the regulations and will not differ between the individual expression hosts. The identity, activity and stability of the end product has to be demonstrated regardless of the production system. The need for pharmaceutical quality assurance, validation of processes, analytical methods and cleaning procedures are essentially the same. 

---